Imagine constantly waking up exhausted even after a full night’s sleep. For millions of people across the world, this is a reality and is caused by obstructive sleep apnea (OSA). Now imagine that this could be helped by simple medications originally developed for diabetes and weight loss. Recent studies suggest that medications called glucagon-like peptide-1 (GLP-1) receptor agonists may offer a promising new approach to managing OSA (Dandamudi et al. 2026).
What Is Obstructive Sleep Apnea?
First of all, what is OSA? OSA is a medical condition where the upper airway repeatedly becomes partially or completely blocked during sleep (Slowik et al. 2025). When the muscles that surround the airway relax during sleep, the throat can narrow or collapse, temporarily interrupting breathing. These interruptions lower oxygen levels and disrupt sleep, often causing loud snoring and excessive daytime tiredness. It can also affect cardiovascular health, mental well-being, quality of life, and driving safety (Slowik et al. 2025).
One of the majour risk factors for OSA is obesity. Obesity can cause things like excess fat at the neck, which can increase the pressure on the upper airway. Additionally, accumulation of abdominal fat caused by obesity can limit diaphragmatic movement, compromise airway stability, and even reduce lung volume. It is estimated that for every 10% increase in body mass index, OSA risk increases by approximately six-fold. This is why using a drug originally developed for weight loss can potentially help reduce the effect of OSA (Fang et al. 2026).
What Are GLP-1 Medications?
GLP-1 is a naturally occurring hormone in the small intestine that is responsible for many key functions, including helping to regulate blood sugar and appetite. It does this by stimulating insulin release, slowing stomach emptying, and increasing feelings of fullness. GLP-1 agonist medications work in a similar way, as they mimic this hormone, helping individuals manage blood sugar and lose weight (Clevel. Clin. 2023). A prominent example of this is the medication tirzepatide, which activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, allowing it to target multiple pathways involved in metabolism and weight regulation (Fang et al. 2026).
How Can GLP-1 Medications Improve Sleep Apnea?
So, how exactly can medications that were originally made for diabetes and weight management improve OSA? Tirzepatide, specifically, may work through three main mechanisms: metabolic regulation, reduced inflammation, and improved upper airway muscle function (Fang et al. 2026).
The first mechanism is metabolic regulation. Since tirzepatide activates both GLP-1 and GIP receptors, it can increase the feelings of fullness and reduce appetite, promoting weight loss. This may reduce fat accumulation around the neck and abdomen, decreasing pressure on the upper airway and making it less likely to collapse during sleep (Fang et al. 2026).
The second mechanism involves reducing inflammation. When the GLP-1 receptor is activated, it can influence AMP-activated protein kinase, which can subsequently suppress the NF-κB signalling pathway. This then reduces pro-inflammatory cytokine production, potentially improving respiratory function (Fang et al. 2026).
Finally, tirzepatide can contribute to neuromuscular improvements. Animal studies have suggested that GLP-1 signalling can increase the tone of the genioglossus, which is a tongue muscle that helps keep the upper airway open. This could then reduce airway collapse during sleep; however, it is important to note that this effect has not been established in humans (Fang et al. 2026).
Importantly, clinical research has supported these potential benefits. A pooled analysis found that GLP-1-based treatment reduced the apnea-hypopnea index, which measures the number of breathing interruptions per hour, by approximately 13.89 interruptions per hour. Additionally, participants experienced an average weight reduction of 12.46 kg. This supports the suggested connection between weight loss and improved OSA (Dandamudi et al. 2026).
A New Approach to Sleep Apnea Treatment!
Although more research is needed to fully understand the mechanisms involved in GLP-1 medications, they still offer a promising approach in managing OSA. By targeting weight, inflammation, and airway muscle function, these medications may not only improve metabolic health. They could also help people achieve a better night’s sleep, which is something I’m sure we can all appreciate.
References
Cleveland Clinic. 2023. “GLP-1 Agonists.” March 7. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.
Dandamudi, Mrunalini, Larissa Lucena, Nicole Norma Gamarra-Valverde, et al. 2026. “Efficacy of GLP-1 Receptor Agonists in Treating Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Cardiometabolic and Respiratory Outcomes.” Sleep & Breathing = Schlaf & Atmung 30 (2): 138. https://doi.org/10.1007/s11325-026-03681-4.
Fang, Qiujie, Yipeng Zhu, Mei Rao, and Peijun Liu. 2026. “GLP-1/GIP Dual Agonist Tirzepatide in Obstructive Sleep Apnea Syndrome: Mechanisms, Evidence, and Clinical Perspectives.” Frontiers in Medicine 13 (April). https://doi.org/10.3389/fmed.2026.1752341.
Slowik, Jennifer M., Abdulghani Sankari, and Jacob F. Collen. 2025. “Obstructive Sleep Apnea.” In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK459252/.
Leave a Reply
You must be logged in to post a comment.